Elsevier

The Lancet

Volume 345, Issue 8954, 8 April 1995, Pages 894-896
The Lancet

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients

https://doi.org/10.1016/S0140-6736(95)90011-XGet rights and content

Abstract

Reported side-effects of tacrolimus, a potent immunosuppressive agent, have not included cardiotoxicity. We describe 5 consecutive paediatric transplant recipients (3 small bowel with or without liver and 2 liver) who received tacrolimus. 2 developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after changing to cyclosporin. In the other 3 patients the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug.

References (11)

  • G. Wiederrecht et al.

    The mechanism of action of FK-506 and cyclosporin A

    Ann New York Acad Sci

    (1994)
  • European FK506 Multicentre Liver Study Group

    Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection

    Lancet

    (1994)
  • K. Abu-Elmagd et al.

    Management of intestinal transplantation in humans

    Transplant Proc

    (1992)
  • Aj Demetris et al.

    Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients

    Transplantation

    (1992)
  • J. McCauley et al.

    The effects of FK506 on renal function after liver transplantation

    Transplant Proc

    (1990)
There are more references available in the full text version of this article.

Cited by (176)

  • What Causes Hypertrophic Cardiomyopathy?

    2022, American Journal of Cardiology
  • Dilated Cardiomyopathy in an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to Sirolimus Switch: A Case Report

    2020, Transplantation Proceedings
    Citation Excerpt :

    It has adverse renal, central nervous system, and vascular side effects that have been previously documented. The cardiotoxic effects of tacrolimus are uncommon and have been most commonly characterized as obstructive or concentric hypertrophic cardiomyopathy described following liver, bowel, renal, and heart transplants [2,3,5]. McLeod et al described development of cardiac hypertrophy shortly after the introduction of tacrolimus, particularly involving the intraventricular septum, which then rapidly progressed to a dilated cardiomyopathy [4].

  • Oral administration of Lactococcus chungangensis inhibits 2,4-dinitrochlorobenzene-induced atopic-like dermatitis in NC/Nga mice

    2016, Journal of Dairy Science
    Citation Excerpt :

    Tacrolimus exerts its therapeutic effect by inhibiting the production of proinflammatory cytokines (Nasr, 2000; Reitamo et al., 2000). In addition, tacrolimus has been reported to cause side effects such as headache, paresthesia, tremor, tinnitus, photophobia, blurred vision, gastrointestinal upset, nausea, vomiting, hyperkalemia, hypertension, and hyperuricemia (Atkison et al., 1995). This highlights the urgent need to develop new therapies that target the underlying causes of AD.

View all citing articles on Scopus
View full text